[go: up one dir, main page]

ITMI981671A0 - Derivati ftalazinici inibitori della fosfodisterasi 4 - Google Patents

Derivati ftalazinici inibitori della fosfodisterasi 4

Info

Publication number
ITMI981671A0
ITMI981671A0 IT98MI001671A ITMI981671A ITMI981671A0 IT MI981671 A0 ITMI981671 A0 IT MI981671A0 IT 98MI001671 A IT98MI001671 A IT 98MI001671A IT MI981671 A ITMI981671 A IT MI981671A IT MI981671 A0 ITMI981671 A0 IT MI981671A0
Authority
IT
Italy
Prior art keywords
phosphodisterase
inhibitors
phthalazine derivatives
phthalazine
derivatives
Prior art date
Application number
IT98MI001671A
Other languages
English (en)
Inventor
Gabriele Norcini
Franco Pellacini
Gabriele Morazzoni
Mauro Napoletano
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Priority to IT98MI001671A priority Critical patent/ITMI981671A1/it
Publication of ITMI981671A0 publication Critical patent/ITMI981671A0/it
Priority to PCT/EP1999/005068 priority patent/WO2000005219A1/en
Priority to NZ507930A priority patent/NZ507930A/xx
Priority to HU0103349A priority patent/HUP0103349A3/hu
Priority to AU49116/99A priority patent/AU766076B2/en
Priority to EP99932894A priority patent/EP1098886A1/en
Priority to EA200100061A priority patent/EA003702B1/ru
Priority to JP2000561175A priority patent/JP2002521371A/ja
Priority to CA002337954A priority patent/CA2337954A1/en
Priority to US09/764,983 priority patent/US6340684B1/en
Priority to IL13949199A priority patent/IL139491A0/xx
Priority to CZ2001240A priority patent/CZ2001240A3/cs
Publication of ITMI981671A1 publication Critical patent/ITMI981671A1/it
Priority to ZA200006577A priority patent/ZA200006577B/xx
Priority to US09/987,266 priority patent/US6498160B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IT98MI001671A 1998-07-21 1998-07-21 Derivati ftalazinici inibitori della fosfodisterasi 4 ITMI981671A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT98MI001671A ITMI981671A1 (it) 1998-07-21 1998-07-21 Derivati ftalazinici inibitori della fosfodisterasi 4
CZ2001240A CZ2001240A3 (cs) 1998-07-21 1999-07-16 Ftalazinové deriváty
EA200100061A EA003702B1 (ru) 1998-07-21 1999-07-16 Производные фталазина в качестве ингибиторов фосфодиэстеразы 4
CA002337954A CA2337954A1 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
HU0103349A HUP0103349A3 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
AU49116/99A AU766076B2 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
EP99932894A EP1098886A1 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
PCT/EP1999/005068 WO2000005219A1 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
JP2000561175A JP2002521371A (ja) 1998-07-21 1999-07-16 ホスホジエステラーゼ４阻害剤としてのフタラジン誘導体
NZ507930A NZ507930A (en) 1998-07-21 1999-07-16 Phthalazine derivatives as PDE 4 inhibitors for the treatment of respiratory diseases and allergic and inflammatory conditions
US09/764,983 US6340684B1 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase 4 inhibitors
IL13949199A IL139491A0 (en) 1998-07-21 1999-07-16 Phthalazine derivatives as phosphodiesterase-4 inhibitors
ZA200006577A ZA200006577B (en) 1998-07-21 2000-11-13 Phthalazine derivatives as phosphodiesterase 4 inhibitors.
US09/987,266 US6498160B2 (en) 1998-07-21 2001-11-14 Phthalazine derivatives as phosphodiesterase 4 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98MI001671A ITMI981671A1 (it) 1998-07-21 1998-07-21 Derivati ftalazinici inibitori della fosfodisterasi 4

Publications (2)

Publication Number Publication Date
ITMI981671A0 true ITMI981671A0 (it) 1998-07-21
ITMI981671A1 ITMI981671A1 (it) 2000-01-21

Family

ID=11380475

Family Applications (1)

Application Number Title Priority Date Filing Date
IT98MI001671A ITMI981671A1 (it) 1998-07-21 1998-07-21 Derivati ftalazinici inibitori della fosfodisterasi 4

Country Status (13)

Country Link
US (2) US6340684B1 (it)
EP (1) EP1098886A1 (it)
JP (1) JP2002521371A (it)
AU (1) AU766076B2 (it)
CA (1) CA2337954A1 (it)
CZ (1) CZ2001240A3 (it)
EA (1) EA003702B1 (it)
HU (1) HUP0103349A3 (it)
IL (1) IL139491A0 (it)
IT (1) ITMI981671A1 (it)
NZ (1) NZ507930A (it)
WO (1) WO2000005219A1 (it)
ZA (1) ZA200006577B (it)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1296984B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
ITMI20000261A1 (it) * 2000-02-16 2001-08-16 Zambon Group Processo per la preparazione di piridiniliden-ftalidi
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN1984904A (zh) * 2004-05-08 2007-06-20 神经能质公司 3－芳基－5,6－二取代哒嗪
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
CA2578996A1 (en) * 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
CA2643044A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US20090181951A1 (en) * 2006-06-15 2009-07-16 Kudos Pharmaceuticals Limited Parp inhibitors
EP2041110A1 (en) * 2006-06-15 2009-04-01 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
EP2041087A1 (en) * 2006-06-15 2009-04-01 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
EP2188278A1 (en) 2007-09-14 2010-05-26 AstraZeneca AB Phthalazinone derivatives
WO2009050469A1 (en) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
ME02640B (me) 2008-10-07 2017-06-20 Kudos Pharm Ltd Farmaceutske formulacije 514
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011007145A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound as parp inhibitor
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
MX365950B (es) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) * 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
GB2063249A (en) * 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
US6207666B1 (en) * 1995-06-07 2001-03-27 Cell Pathways, Inc. Method for treating a patient having precancerous lesion with 4-phenylphthalazine derivatives
WO1998027066A1 (en) 1996-12-18 1998-06-25 Neurogen Corporation Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
IT1296984B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
ITMI981670A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4

Also Published As

Publication number Publication date
US6498160B2 (en) 2002-12-24
AU766076B2 (en) 2003-10-09
US6340684B1 (en) 2002-01-22
EP1098886A1 (en) 2001-05-16
AU4911699A (en) 2000-02-14
WO2000005219A1 (en) 2000-02-03
NZ507930A (en) 2002-11-26
IL139491A0 (en) 2001-11-25
ZA200006577B (en) 2002-04-24
CZ2001240A3 (cs) 2001-09-12
EA003702B1 (ru) 2003-08-28
JP2002521371A (ja) 2002-07-16
US20020058662A1 (en) 2002-05-16
EA200100061A1 (ru) 2001-08-27
HUP0103349A3 (en) 2003-01-28
HUP0103349A2 (hu) 2002-02-28
CA2337954A1 (en) 2000-02-03
ITMI981671A1 (it) 2000-01-21

Similar Documents

Publication Publication Date Title
ITMI981671A0 (it) Derivati ftalazinici inibitori della fosfodisterasi 4
ITMI981670A0 (it) Derivati ftalazinici inibitori della fosfodiesterasi 4
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
NO20010193L (no) Tiobenzimidazol-derivater
ATE236136T1 (de) Benzosulfonderivate
DE69934788D1 (de) Biozide benzylbiphenylderivative
IT1312558B1 (it) Derivati di alfa-chetoammidi
NO20010046L (no) Dolastatin-15-derivater
ATE259810T1 (de) Phenyl-xanthinderivate
EE9800219A (xx) Uued 19-nor-pregneeni derivaadid
NO20012960D0 (no) Farnesylproteintransferase-inhibitorer
IT1296985B1 (it) Derivati benzazinici inibitori della fosfodiesterasi 4
DE69911152D1 (de) Symmetrischer Verstärker
NO20013237D0 (no) 3,3-biarylpiperidin og 2,2-biarylmorfolinderivater
ITMI982216A0 (it) Derivati benzazinici inibitori della fosfodiesterasi 4
DE69939359D1 (de) Verstärker
ITMI982319A0 (it) Derivati triciclici inibitori della fosfodiesterasi 4
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
IT1277073B1 (it) Derivati antraciclinici
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
ATE233253T1 (de) Chromanderivate
DK1060183T3 (da) 5-deoxycytidinderivater
IT1273610B (it) Derivati della purporogallina
IT1289621B1 (it) Impiego di derivati della tetraidroisochinolina
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate